Related Experiment Videos
Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue
Therapeutic Drug Monitoring
|January 1, 1980
Summary
Monitoring methotrexate (MTX) levels and kidney function is crucial for preventing severe toxicity in cancer patients. Early identification of at-risk individuals and prompt intervention strategies can mitigate serious side effects from MTX therapy.
Area of Science:
- Pharmacology
- Oncology
- Clinical Toxicology
Background:
- Methotrexate (MTX) is a vital chemotherapeutic agent used in various cancer treatments.
- High-dose MTX therapy necessitates careful management due to its potential for severe toxicity.
- Understanding MTX pharmacokinetics and toxicity is critical for patient safety.
Purpose of the Study:
- To review therapeutic drug monitoring (TDM) procedures for moderate and high-dose methotrexate (MTX) therapy.
- To identify key indicators for predicting MTX toxicity.
- To outline preventive strategies against MTX-induced toxicity.
Main Methods:
- Review of existing literature on MTX TDM protocols.
- Analysis of factors influencing MTX clearance and toxicity (serum MTX levels, creatinine clearance, weight loss).
- Evaluation of supportive care measures (citrovorum factor rescue, hydration, urine alkalinization).
Main Results:
- Serum MTX levels, creatinine clearance, and weight loss are indicators of hematological toxicity risk.
- Increased citrovorum factor, hydration, and urine alkalinization enhance MTX clearance and prevent precipitation.
- MTX toxicity is linked to prolonged drug retention; initial clearance correlates with creatinine clearance.
Conclusions:
- Careful drug monitoring is essential for the safe and effective use of high-dose MTX.
- Patients with impaired renal function require particular attention due to MTX-induced nephrotoxicity.
- Further research is needed to fully elucidate the complex mechanisms of MTX toxicity and efficacy.